Minutes of the 125th meeting of the EMA Management Board
Submitted by Anonymous (not verified) on 10 January 2025 - 13:41
Minutes of the 125th meeting of the EMA Management Board
Parallel scientific advice processes
Submitted by Anonymous (not verified) on 10 January 2025 - 13:41
Parallel scientific advice processes
CHMP work plan 2025
Submitted by Anonymous (not verified) on 10 January 2025 - 13:24
CHMP work plan 2025
New EU rules for health technology assessments become effective
Submitted by Anonymous (not verified) on 10 January 2025 - 13:03
New EU rules for health technology assessments become effective
Health technology assessment bodies
Submitted by Anonymous (not verified) on 10 January 2025 - 13:02
Health technology assessment bodies
EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) - Authorisation status
Submitted by Anonymous (not verified) on 10 January 2025 - 8:36
EudraVigilance eXtended Medicinal Product Dictionary (XEVMPD) - Authorisation status
Electronic submission of Article 57(2) data: questions and answers
Submitted by Anonymous (not verified) on 10 January 2025 - 8:36
Electronic submission of Article 57(2) data: questions and answers
Chapter 5: eXtended EudraVigilance Product Report Acknowledgement Message - Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA
Submitted by Anonymous (not verified) on 10 January 2025 - 8:35
Chapter 5: eXtended EudraVigilance Product Report Acknowledgement Message - Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA
Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA
Submitted by Anonymous (not verified) on 10 January 2025 - 8:32
Chapter 3.II: XEVPRM detailed user guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA
Committee for Advanced Therapies (CAT): 6-8 November 2024, European Medicines Agency, Amsterdam, the Netherlands, from 6 November 2024 to 8 November 2024
Submitted by Anonymous (not verified) on 9 January 2025 - 15:00
Committee for Advanced Therapies (CAT): 6-8 November 2024, European Medicines Agency, Amsterdam, the Netherlands, from 6 November 2024 to 8 November 2024